Literature DB >> 7793887

Potential use of a simplified method for determination of itraconazole levels in plasma and esophageal tissue by using high-performance liquid chromatography.

R O Darouiche1, A Setoodeh, E J Anaissie.   

Abstract

A simplified high-performance liquid chromatography assay was developed for determination of itraconazole levels in plasma and esophageal tissue in four patients with AIDS who had been receiving daily oral doses of 100 mg of itraconazole in solution for at least 3 weeks for therapy of esophageal candidiasis. Itraconazole levels were about three times higher in esophageal tissue than in plasma (means +/- standard errors of 0.69 +/- 0.50 micrograms/g and 0.24 +/- 0.16 micrograms/ml, respectively; P = 0.04). This method is quick (it requires only 1 h for completion) and sensitive (the limits of detectability for itraconazole in plasma and esophageal tissue are 0.005 micrograms/ml and 0.01 micrograms/g, respectively), and it can be reliably used in clinical and research settings (accuracy, > 95%; absolute recovery from biological samples, 80 to 90%; coefficient of variation, 3.3 to 6.6%).

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7793887      PMCID: PMC162619          DOI: 10.1128/AAC.39.3.757

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

1.  The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects.

Authors:  A Van Peer; R Woestenborghs; J Heykants; R Gasparini; G Gauwenbergh
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 2.  Treatment of gastrointestinal infections.

Authors:  J W Pape
Journal:  AIDS       Date:  1988       Impact factor: 4.177

3.  Early experience with itraconazole in vitro and in patients: pharmacokinetic studies and clinical results.

Authors:  B Dupont; E Drouhet
Journal:  Rev Infect Dis       Date:  1987 Jan-Feb

Review 4.  Activity of orally, topically, and parenterally administered itraconazole in the treatment of superficial and deep mycoses: animal models.

Authors:  J Van Cutsem; F Van Gerven; P A Janssen
Journal:  Rev Infect Dis       Date:  1987 Jan-Feb

5.  Comparison of itraconazole and fluconazole in treatment of cryptococcal meningitis and candida pyelonephritis in rabbits.

Authors:  J R Perfect; D V Savani; D T Durack
Journal:  Antimicrob Agents Chemother       Date:  1986-04       Impact factor: 5.191

Review 6.  The clinical pharmacokinetics of itraconazole: an overview.

Authors:  J Heykants; A Van Peer; V Van de Velde; P Van Rooy; W Meuldermans; K Lavrijsen; R Woestenborghs; J Van Cutsem; G Cauwenbergh
Journal:  Mycoses       Date:  1989       Impact factor: 4.377

7.  The pharmacokinetics of oral itraconazole in AIDS patients.

Authors:  D Smith; V van de Velde; R Woestenborghs; B G Gazzard
Journal:  J Pharm Pharmacol       Date:  1992-07       Impact factor: 3.765

8.  Itraconazole for experimental pulmonary aspergillosis: comparison with amphotericin B, interaction with cyclosporin A, and correlation between therapeutic response and itraconazole concentrations in plasma.

Authors:  J Berenguer; N M Ali; M C Allende; J Lee; K Garrett; S Battaglia; S C Piscitelli; M G Rinaldi; P A Pizzo; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

9.  Fluconazole compared with ketoconazole for the treatment of Candida esophagitis in AIDS. A randomized trial.

Authors:  L Laine; R H Dretler; C N Conteas; C Tuazon; F M Koster; F Sattler; K Squires; M Z Islam
Journal:  Ann Intern Med       Date:  1992-10-15       Impact factor: 25.391

10.  Comparison of high performance liquid chromatographic and microbiological methods for determination of itraconazole.

Authors:  D W Warnock; A Turner; J Burke
Journal:  J Antimicrob Chemother       Date:  1988-01       Impact factor: 5.790

View more
  6 in total

1.  Development, validation, and routine application of a high-performance liquid chromatography method coupled with a single mass detector for quantification of itraconazole, voriconazole, and posaconazole in human plasma.

Authors:  Lorena Baietto; Antonio D'Avolio; Giusi Ventimiglia; Francesco Giuseppe De Rosa; Marco Siccardi; Marco Simiele; Mauro Sciandra; Giovanni Di Perri
Journal:  Antimicrob Agents Chemother       Date:  2010-06-07       Impact factor: 5.191

2.  Isocratic high-performance liquid chromatographic method with ultraviolet detection for simultaneous determination of levels of voriconazole and itraconazole and its hydroxy metabolite in human serum.

Authors:  GholamAli Khoschsorur; Franz Fruehwirth; Sieglinde Zelzer
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

3.  Safety, pharmacokinetics, and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasis.

Authors:  Andreas H Groll; Lauren Wood; Maureen Roden; Diana Mickiene; Christine C Chiou; Ellen Townley; Luqman Dad; Stephen C Piscitelli; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

Review 4.  Tissue penetration of antifungal agents.

Authors:  Timothy Felton; Peter F Troke; William W Hope
Journal:  Clin Microbiol Rev       Date:  2014-01       Impact factor: 26.132

5.  Targeting the Hedgehog Pathway Using Itraconazole to Prevent Progression of Barrett's Esophagus to Invasive Esophageal Adenocarcinoma.

Authors:  Ronan J Kelly; Amir M Ansari; Tomoharu Miyashita; Marianna Zahurak; Frank Lay; A Karim Ahmed; Louis J Born; Maryam K Pezhouh; Kevan J Salimian; Christopher Ng; Aerielle E Matsangos; Anne-Heloise Stricker-Krongrad; Ken-Ichi Mukaisho; Guy P Marti; Christine H Chung; Marcia I Canto; Michelle A Rudek; Stephen J Meltzer; John W Harmon
Journal:  Ann Surg       Date:  2021-06-01       Impact factor: 13.787

6.  Development of PLGA-based itraconazole injectable nanospheres for sustained release.

Authors:  Xiaomei Bian; Su Liang; Jyothy John; Cheng-Hui Hsiao; Xin Wei; Dong Liang; Huan Xie
Journal:  Int J Nanomedicine       Date:  2013-11-21
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.